Docket No.: 217318US0 DIV

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :

Hiroshi KAYAKIRI, et al. : ATTN: APPLICATION DIVISION

SERIAL NO: NEW U.S. APPLICATION :

FILED: HEREWITH :

FOR: SULFONAMIDE COMPOUNDS AND PHARMACEUTICAL USE THEREOF

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as indicated below.

IN THE CLAIMS

Please amend Claims 13 and 14 as follows.

--13. (Amended) A method for treating a disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity or antiallergic activity, comprising:

administering an effective amount of the sulfonamide compound of claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.

14. (Amended) A method for producing a therapeutic agent comprising admixing the sulfonamide compound of claim 1 with a pharmaceutically acceptable excipient or carrier.--

Please add the following new claims:

- --15. (New) A method for reducing the level of blood sugar comprising administering an effective amount of the sulfonamide compound of claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof for a time and under conditions effective to reduce the level of blood sugar.
- 16. (New) A method for inhibiting cGDP-PDE activity comprising administering an effective amount of the sulfonamide compound of claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof for a time and under conditions effective to inhibit cGDP-PDE activity.
- 17. (New) A method for relaxing smooth muscle, inducing bronchodilation, inducing vasodilation, suppressing smooth muscle cell activity or inducing antiallergic activity comprising

administering an effective amount of the sulfonamide compound of claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof for a time and under conditions effective to relax smooth muscle, induce bronchodilation, induce vasodilation, suppress smooth muscle cell activity or induce antiallergic activity.

- 18. (New) The composition of Claim 12 that is in a form suitable for oral, parenteral, external, or local administration.
- 19. (New) The composition of Claim 12 that is in the form of a capsule, tablet, sugar-coated tablet, granule, suppository, liquid, solvate, lotion, suspension, emulsion, ointment, or gel.
- 20. (New) The composition of Claim 12, further comprising a adjuvant auxiliary, auxiliary substance, stabilizer, moistening agent, emulsifier, or buffering agent.--

REMARKS

Claims 1-20 are pending. Claims 13 and 14 have been amended to place these claims in better condition for examination. Support for new Claims 15-17 is found in the disclosure on pages 40-42 and 288-289. Support for new composition Claims 18-20 is found on pages 41-42 of the specification. Accordingly, the Applicants do not believe that any new matter has been added. Applicants now respectfully request an early examination on the merits.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.
Thomas Cumingle

Norman F. Oblon Attorney of Record

Registration No. 24,618

Thomas M. Cunningham Registration No. 45,394

Tel: 703-413-3000 Fax: 703-413-2220 NFO:TMC:ksh

I:\atty\Tmc\2001-12\217318US-Prel Amend.wpd

22850

Marked-Up Copy

Docket No.: 217318US0 DIV

Serial No: New Application

Amendment Filed: _ Herewith

IN THE CLAIMS

Please amend Claims 13 and 14 as follows:

--13. (Amended) A method for treating a disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity or antiallergic activity, comprising:

administering an effective amount [by the use] of the sulfonamide compound of claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.

14. (Amended) A method for producing a therapeutic agent comprising admixing the sulfonamide compound of claim 1 with a pharmaceutically acceptable excipient or carrier [use of the sulfonamide compound of claim 1 or a pharmaceutically acceptable salt thereof for the production of a therapeutic agent or a disease treatable based on a blood sugar level-depressing activity, or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity or antiallergic activity].--

--Claims 15-20 (New).--